194 related articles for article (PubMed ID: 30420441)
1. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.
Gerke T; Beltran H; Wang X; Lee GM; Sboner A; Karnes RJ; Klein EA; Davicioni E; Yousefi K; Ross AE; Börnigen D; Huttenhower C; Mucci LA; Trock BJ; Sweeney CJ
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):584-590. PubMed ID: 30420441
[TBL] [Abstract][Full Text] [Related]
2. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
3. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
4. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
5. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy.
Perrouin-Verbe MA; Schoentgen N; Talagas M; Garlantezec R; Uguen A; Doucet L; Rosec S; Marcorelles P; Potier-Cartereau M; Vandier C; Ferec C; Fromont G; Fournier G; Valeri A; Mignen O
Prostate; 2019 Dec; 79(16):1793-1804. PubMed ID: 31475744
[TBL] [Abstract][Full Text] [Related]
7. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
8. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
9. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
11. α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study.
Barry M; Dhillon PK; Stampfer MJ; Perner S; Ma J; Giovannucci E; Kurth T; Mucci LA; Rubin MA
Prostate; 2012 Feb; 72(3):301-6. PubMed ID: 21713964
[TBL] [Abstract][Full Text] [Related]
12. Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.
Friedlander TW; Welty C; Anantharaman A; Schonhoft JD; Jendrisak A; Lee J; Li P; Hough J; Stromlund A; Edwards M; Sangar S; Kobayashi Y; Simko J; Farrokhian N; Lindquist K; Greene S; Ontiveros P; Graf R; Rodriquez A; Suraneni M; Wang Y; Landers M; Carroll P; Cooperberg MR; Dittamore R; Paris PL
J Urol; 2019 Oct; 202(4):732-741. PubMed ID: 31216253
[TBL] [Abstract][Full Text] [Related]
13. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
14. PBX3 is a putative biomarker of aggressive prostate cancer.
Ramberg H; Grytli HH; Nygård S; Wang W; Ögren O; Zhao S; Løvf M; Katz B; Skotheim RI; Bjartell A; Eri LM; Berge V; Svindland A; Taskén KA
Int J Cancer; 2016 Oct; 139(8):1810-20. PubMed ID: 27273830
[TBL] [Abstract][Full Text] [Related]
15. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.
Rounbehler RJ; Berglund AE; Gerke T; Takhar MM; Awasthi S; Li W; Davicioni E; Erho NG; Ross AE; Schaeffer EM; Klein EA; Karnes RJ; Jenkins RB; Cleveland JL; Park JY; Yamoah K
Cancer Epidemiol Biomarkers Prev; 2018 Nov; 27(11):1376-1383. PubMed ID: 30108099
[No Abstract] [Full Text] [Related]
16. Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.
Nguyen HG; Welty C; Lindquist K; Ngo V; Gilbert E; Bengtsson H; Magi-Galluzzi C; Jean-Gilles J; Yao J; Cooperberg M; Messing E; Klein EA; Carroll PR; Paris PL
J Urol; 2018 Mar; 199(3):719-725. PubMed ID: 28941923
[TBL] [Abstract][Full Text] [Related]
17. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
[TBL] [Abstract][Full Text] [Related]
18. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
Hegde JV; Veruttipong D; Said JW; Reiter RE; Steinberg ML; King CR; Kishan AU
Urology; 2017 Sep; 107():171-177. PubMed ID: 28552819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
